CAR-T Meeting 2024 | Using the available repertoire of bispecific antibodies for treating multiple myeloma
Paola Neri
• 17 Feb 2024
In this video, Paola Neri, MD, PhD, University of Calgary, Calgary, Canada, outlines the bispecific antibodies available for treating multiple myeloma (MM) and suggests how they can be incorporated into the current treatment paradigm. Dr Neri highlights that dual targeting of antigens may not be an optimal approach and that BCMA should likely remain the first target when treating patients. This interview took place at the EBMT-EHA 6th European CAR T-cell Meeting in Valencia, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultancy: Janssen, BMS, Pfizer, Sanofi; Honoraria: Janssen, BMS, Pfizer, Sanofi.
